(Rac)-EC5026

Cat. No.: HY-135653A

CAS No.: 1809885-55-9

Molecular Formula: $C_{18}H_{23}F_4N_3O_3$

Molecular Weight: 405.39

Target: Epoxide Hydrolase

Pathway: Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (616.69 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.4668 mL	12.3338 mL	24.6676 mL
5 mM	0.4934 mL	2.4668 mL	4.9335 mL
10 mM	0.2467 mL	1.2334 mL	2.4668 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (5.13 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (5.13 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.13 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a K_i of 0.06 nM. (Rac)-EC5026 can be used for the research of Parkinson's disease and dementia with Lewy Bodies (DLB)[1].

IC_{50} & Target

Ki: 0.06 nM (sEH)][1]

In Vitro

(Rac)-EC5026 inhibits soluble epoxide hydrolase (sEH), with a K_i of 0.06 nM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Hammock BD, et, al. Methods of inhibiting formation of alpha synuclein aggregates. WO2019156991A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA